Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.
Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
JMIR Res Protoc. 2024 Oct 8;13:e57888. doi: 10.2196/57888.
Glaucoma is a chronic progressive optic neuropathy that necessitates lifelong treatment to reduce the decline of the optic nerve. Due to the extended and continuous treatments required for patients, complementary therapies are often considered alongside conventional treatments to enhance the effectiveness of the treatment. Acupuncture has demonstrated the potential to lower intraocular pressure in previous clinical trials, making it a promising glaucoma intervention.
The primary objective of this study is to conduct a single-center randomized control trial involving patients with glaucoma. Acupuncture will be evaluated as an adjunctive therapy. The trial aims to explore its effectiveness for glaucoma.
In this single-center randomized controlled trial, participants (N=50) with primary open-angle glaucoma will be randomly assigned to the treatment group, receiving ophthalmic acupuncture with "De Qi" sensation, or the control group, receiving minimum acupuncture stimulation on nonophthalmic acupoints. The intervention will consist of weekly acupuncture treatments for a total of 6 sessions. Participants will be assessed at 8 time points, which are baseline, during the intervention (6 times), and at a 3-month follow-up. The primary outcome measure is a change in the intraocular pressure before and after each acupuncture treatment. Secondary outcomes will include measurements of heart rate and blood pressure before and after acupuncture, best-corrected visual acuity, visual field, optical coherence tomography, optical coherence tomography angiography, the Glaucoma Symptom Scale, and the Glaucoma Quality of Life-15 questionnaire.
Recruitment of participants for the trial commenced on June 28, 2023. A total of 10 participants have been enrolled to test the feasibility of the experiment. We anticipate that the preliminary data from this trial will be completed by December 2025.
This trial uses rigorous methodology and comprehensive outcome measurements to assess the clinical efficacy of acupuncture as an adjunctive therapy for glaucoma, providing valuable insights for future clinical treatment guidelines.
ClinicalTrials.gov NCT05753137; https://clinicaltrials.gov/study/NCT05753137.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/57888.
青光眼是一种慢性进行性视神经病变,需要终身治疗以减缓视神经的衰退。由于患者需要长期持续治疗,因此通常会考虑将补充疗法与传统疗法结合使用,以提高治疗效果。针灸在以前的临床试验中已显示出降低眼压的潜力,因此是一种有前途的青光眼干预措施。
本研究的主要目的是对青光眼患者进行单中心随机对照试验。将评估针灸作为辅助疗法的效果。该试验旨在探索其治疗青光眼的有效性。
在这项单中心随机对照试验中,将 50 名原发性开角型青光眼患者随机分为治疗组(接受有“得气”感的眼部针灸)和对照组(接受非眼部穴位的最小针灸刺激)。干预措施为每周进行 6 次针灸治疗,共 6 次。参与者将在 8 个时间点进行评估,分别是基线、干预期间(6 次)和 3 个月随访。主要结局指标是每次针灸治疗前后眼压的变化。次要结局指标包括针灸前后心率和血压的测量、最佳矫正视力、视野、光学相干断层扫描、光学相干断层扫描血管造影、青光眼症状量表和青光眼生活质量-15 问卷。
该试验于 2023 年 6 月 28 日开始招募参与者。目前已纳入 10 名参与者,以测试该实验的可行性。预计该试验的初步数据将于 2025 年 12 月完成。
本试验采用严格的方法和全面的结局测量来评估针灸作为青光眼辅助治疗的临床疗效,为未来的临床治疗指南提供有价值的参考。
ClinicalTrials.gov NCT05753137;https://clinicaltrials.gov/study/NCT05753137。
国际注册报告标识符(IRRID):DERR1-10.2196/57888。